- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06564844
Une étude randomisée de phase III sur l'adjuvant Dato-DXd en association avec le Rilvegostomig ou le Rilvegostomig en monothérapie par rapport à la norme de soins, après une résection complète de la tumeur, chez des participants atteints d'un adénocarcinome de stade I CPNPC qui sont positifs à l'ADNc ou présentent des caractéristiques pathologiques à haut risque (TROPION-Lung12)
Une étude mondiale de phase III, randomisée, ouverte, sur l'adjuvant Datopotamab Deruxtecan (Dato-DXd) en association avec le Rilvegostomig ou le Rilvegostomig en monothérapie par rapport à la norme de soins, après une résection complète de la tumeur, chez des participants atteints d'un cancer du poumon non à petites cellules d'adénocarcinome de stade I Qui sont positifs à l'ADNct ou présentent des caractéristiques pathologiques à haut risque (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Barretos, Brésil, 14784-057
- Research Site
-
Brasília, Brésil, 70200-730
- Research Site
-
Florianópolis, Brésil, 88034-000
- Research Site
-
São Paulo, Brésil, 01323-903
- Research Site
-
Teresina, Brésil, 64049-200
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3J4
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Research Site
-
-
-
-
-
Bunkyō City, Japon, 113-8603
- Research Site
-
Chiba, Japon, 260-0877
- Research Site
-
Chūōku, Japon, 104-0045
- Research Site
-
Fukuoka, Japon, 812-8582
- Research Site
-
Hidaka-shi, Japon, 350-1298
- Research Site
-
Hiroshima, Japon, 734-8551
- Research Site
-
Hiroshima, Japon, 730-8518
- Research Site
-
Iwakuni-shi, Japon, 740-8510
- Research Site
-
Kashiwa, Japon, 277-8577
- Research Site
-
Kitaadachi-gun, Japon, 362-0806
- Research Site
-
Kobe, Japon, 650-0017
- Research Site
-
Kumamoto, Japon, 860-8556
- Research Site
-
Kōtoku, Japon, 135-8550
- Research Site
-
Nagoya, Japon, 464-8681
- Research Site
-
Niigata, Japon, 951-8566
- Research Site
-
Osakasayama-shi, Japon, 589-8511
- Research Site
-
Sapporo, Japon, 003-0804
- Research Site
-
Sendai, Japon, 980-8574
- Research Site
-
Sendai, Japon, 980-0873
- Research Site
-
Wakayama, Japon, 641-8510
- Research Site
-
Yokohama, Japon, 241-8515
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaisie, 59100
- Research Site
-
Kuala Lumpur, Malaisie, 50586
- Research Site
-
Kuching, Malaisie, 93586
- Research Site
-
-
-
-
-
Kaohsiung City, Taïwan, 80756
- Research Site
-
Taipei, Taïwan, 10002
- Research Site
-
Taipei, Taïwan, 112
- Research Site
-
Taipei, Taïwan, 114
- Research Site
-
Taoyuan, Taïwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thaïlande, 10400
- Research Site
-
Bangkoknoi, Thaïlande, 10700
- Research Site
-
Banphaeo, Thaïlande, 74120
- Research Site
-
Dusit, Thaïlande, 10300
- Research Site
-
Hat Yai, Thaïlande, 90110
- Research Site
-
Muang, Thaïlande, 50200
- Research Site
-
Muang, Thaïlande, 40002
- Research Site
-
Ratchathewi, Thaïlande, 10400
- Research Site
-
-
-
-
-
Ankara, Turquie (Türkiye), 06280
- Research Site
-
Ankara, Turquie (Türkiye), 06010
- Research Site
-
Mersin, Turquie (Türkiye), 33240
- Research Site
-
-
-
-
-
Hanoi, Viêt Nam, 100000
- Research Site
-
Ho Chi Minh City, Viêt Nam, 700000
- Research Site
-
Hà Nội, Viêt Nam, 100000
- Research Site
-
Vinh, Viêt Nam, 460000
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85724
- Research Site
-
-
California
-
Duarte, California, États-Unis, 91010
- Research Site
-
Glendale, California, États-Unis, 91204
- Research Site
-
Los Angeles, California, États-Unis, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, États-Unis, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Research Site
-
St. Petersburg, Florida, États-Unis, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Research Site
-
Evanston, Illinois, États-Unis, 60201
- Research Site
-
Zion, Illinois, États-Unis, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, États-Unis, 48334
- Research Site
-
Grand Rapids, Michigan, États-Unis, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55407
- Research Site
-
-
Montana
-
Billings, Montana, États-Unis, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, États-Unis, 13057
- Research Site
-
Mineola, New York, États-Unis, 11501
- Research Site
-
New York, New York, États-Unis, 10016
- Research Site
-
New York, New York, États-Unis, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, États-Unis, 18015
- Research Site
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Research Site
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37920
- Research Site
-
Memphis, Tennessee, États-Unis, 38120
- Research Site
-
Nashville, Tennessee, États-Unis, 37203
- Research Site
-
-
Texas
-
Austin, Texas, États-Unis, 78745
- Research Site
-
Dallas, Texas, États-Unis, 75231
- Research Site
-
Houston, Texas, États-Unis, 77030
- Research Site
-
San Antonio, Texas, États-Unis, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
Autres noms:
Rilvegostomig IV (intravenous)
Autres noms:
|
|
Expérimental: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
Autres noms:
|
|
Comparateur actif: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Délai: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Délai: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Délai: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Délai: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
Délai: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Délai: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Délai: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
Délai: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- Chercheur principal: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs, glandulaires et épithéliales
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Carcinome
- Carcinome bronchique
- Tumeurs bronchiques
- Carcinome pulmonaire non à petites cellules
- Adénocarcinome
- Acides aminés, peptides et protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Hydrocarbures, cyclique
- Glucides
- Alcaloïdes
- Podophyllotoxine
- Tétrahydronaphtalènes
- Naphtalenes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glucosides
- Glycosides
- Indoles
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Complexes de coordination
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Acides aminés, acides
- Acides aminés
- Acides aminés, dicarboxylique
- Alcaloïdes Vinca
- Alcaloïdes de la secologane tryptamine
- Alcaloïdes indole
- Indolizidines
- Indolizines
- Composés en platine
- Vinorelbine
- Pémétrexed
- Étoposide
- Carboplatine
- Cisplatine
Autres numéros d'identification d'étude
- D926TC00001
- 2024-512195-35-00 (Identificateur de registre: CTIS)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .